Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 7Neuroblastoma 4Hematologic Neoplasms 4Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Graft vs Host Disease 3Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Hodgkin Disease 2Ganglioneuroblastoma 2Burkitt Lymphoma 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Teratoma 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Mast-Cell 1Leukemia, Lymphoid 1Leukemia 1

Interventions

Cyclophosphamide 3Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Biopsy 2pirtobrutinib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1ibrutinib 1fludarabine phosphate 1fludarabine 1blinatumomab 1Thiotepa 1Surveys and Questionnaires 1Sirolimus 1Mycophenolic Acid 1Methotrexate 1Cyclosporins 1Cyclosporine 1Busulfan 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Lymphoid × Thiotepa × Clear all
NCT03970096 2026-03-12

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Fred Hutchinson Cancer Center

Phase 2 Recruiting
120 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡